Scholarlink

<p>Platelet transfusion is a cornerstone of modern supportive care, yet its application is characterized by significant practice variation and uncertainty regarding optimal strategies. This comprehensive review synthesizes current evidence to delineate a more nuanced, physiologically informed approach to platelet therapy. A paradigm shift is underway, moving from uniform count-based triggers toward more restrictive, evidence-based practices; this includes prophylactic thresholds of &lt; 10 × 10⁹/L in stable hematology-oncology patients and therapeutic-only strategies in select populations. In massive hemorrhage, fixed-ratio resuscitation protocols incorporating early platelet administration are critical for improving hemostasis. Conversely, high-quality evidence now defines populations where transfusion may be harmful, including in thrombotic microangiopathies like TTP, heparin-induced thrombocytopenia, and spontaneous intracerebral hemorrhage in patients on antiplatelet agents. The utility of viscoelastic assays in guiding goal-directed therapy and the potential of novel products such as pathogen-reduced, cold-stored, and cryopreserved platelets to mitigate the limitations of conventional storage are also critically examined. This review provides clinicians with a framework to navigate these complexities, emphasizing a context-dependent strategy that balances hemostatic benefit against potential harm to optimize patient outcomes and steward a precious resource.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The evolving landscape of platelet therapy: risks, innovations, and clinical judgment

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月15日

查看全文
  • Ali Mushtaq,
  • Moises Salgado de la Mora,
  • Al-Homam Dabaliz,
  • Zaher Otrock,
  • Deborah Tolich,
  • Moises Auron

摘要

Platelet transfusion is a cornerstone of modern supportive care, yet its application is characterized by significant practice variation and uncertainty regarding optimal strategies. This comprehensive review synthesizes current evidence to delineate a more nuanced, physiologically informed approach to platelet therapy. A paradigm shift is underway, moving from uniform count-based triggers toward more restrictive, evidence-based practices; this includes prophylactic thresholds of < 10 × 10⁹/L in stable hematology-oncology patients and therapeutic-only strategies in select populations. In massive hemorrhage, fixed-ratio resuscitation protocols incorporating early platelet administration are critical for improving hemostasis. Conversely, high-quality evidence now defines populations where transfusion may be harmful, including in thrombotic microangiopathies like TTP, heparin-induced thrombocytopenia, and spontaneous intracerebral hemorrhage in patients on antiplatelet agents. The utility of viscoelastic assays in guiding goal-directed therapy and the potential of novel products such as pathogen-reduced, cold-stored, and cryopreserved platelets to mitigate the limitations of conventional storage are also critically examined. This review provides clinicians with a framework to navigate these complexities, emphasizing a context-dependent strategy that balances hemostatic benefit against potential harm to optimize patient outcomes and steward a precious resource.